Based on the aforementioned findings, we supposed that anti‐TIGIT and anti‐CD96 could restore the anti‐tumor immunity of CD8+ T cells, without inferiority to anti‐PD1, presenting unprecedented potential for them to become ICB targets for clinical use. This evidence concerns the gene CD8A and neoplasm.